Comparative Pharmacology
Head-to-head clinical analysis: SHEUR versus TZ 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SHEUR versus TZ 3.
SHEUR vs TZ-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SHEUR is a small molecule inhibitor of the bromodomain and extraterminal (BET) family proteins, specifically BRD2, BRD3, BRD4, and BRDT. By binding to acetyl-lysine recognition motifs, it disrupts chromatin remodeling and transcriptional regulation, leading to reduced expression of oncogenes such as MYC.
(S)-3-(4-(2-((3-fluorophenyl)amino)-2-oxoethyl)piperazin-1-yl)-N,N-dimethylpropanamide; selectively inhibits the interaction between the PD-1/PD-L1 immune checkpoint, blocking the PD-1/PD-L1 pathway and restoring antitumor T-cell function.
No standard dosing available; SHEUR is not a recognized pharmaceutical agent.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life: 4.5 hours; clinically, steady-state reached within 24 hours.
12–18 hours (terminal). Steady-state achieved in ~3 days. Extended to ~30 hours in severe renal impairment.
Renal: 70% unchanged; Biliary/Fecal: 30% as metabolites.
Primarily renal (60–70% unchanged), with 20–30% biliary/fecal, and <10% metabolized. Dosage adjustment required in renal impairment.
Category C
Category C
Unknown
Unknown